Clinical Trials Directory

Trials / Completed

CompletedNCT02281409

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Memorial Sloan Kettering Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to find out what effects, good and/or bad, KW-0761, an investigational drug, has on the patient and their cancer.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMogamulizumab (KW-0761)

Timeline

Start date
2014-10-01
Primary completion
2020-02-01
Completion
2020-02-01
First posted
2014-11-03
Last updated
2021-04-23
Results posted
2021-04-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02281409. Inclusion in this directory is not an endorsement.